СПИСОК ЛИТЕРАТУРЫ

Берштейн Л.М., Имянитов Е.Н. Полиморфизм генов ферментов стерои-догенеза и риск развития злокачественных опухолей. Вопр. онкол, 1999, т. 45, с. 213-218.

ДильманВ.М. Эндокринологическая онкология. Изд. 2-е, Л.: Медицина, 1983.

Заридзе Д.Г. Канцерогенез. М.: Медцина, 2004.

Имянитов Е.Н., Князев П.Г. Роль антионкогенов в опухолевом процессе. Эксперим. онкол., 1992, № 5, с. 3-17.

Имянитов Е.Н., Комочков И.В., Лыщев А.А., Того А.В. Молекулярная и клиническая онкология: точки соприкосновения. Эксперим. онкол., 1993, № 5, с. 3-8.

Имянитов Е.Н., Калиновский В.П., Князев П.Г., Лыщев А.А., Монахов А.С., Новиков Л.Б., Того А.В., Федоров С.Н., Хансон. К.П. Молекулярная генетика опухолей человека. Вопр. онкол., 1997, т. 43, № 1, с. 95-101.

Имянитов Е.Н., Хансон К.П. Молекулярные аспекты патогенеза первично-множественных опухолей. Росс, онкол. журн., 1998, № 5, с. 47—51.

Киселев Ф.Л. Вирусы папиллом человека как этиологический фактор рака шейки матки: значение для практики здравоохранения. Вопр. вирусол., 1997, т. 42, № 6, с. 248-251.

Мерабишвили В.М., Дятченко О.Т. Статистика рака лёгкого (заболеваемость, смертность, выживаемость). Практич. онкол., 2000, т. 3, с. 3—7.

Мерабишвили В.М. (ред.). Деятельность онкологической службы С.-Петербурга в 2000 г. СПб, 2001.

Моисеенко В.М., Семиглазов В.Ф., ТюляндинСА. Современное лекарственное лечение местно-распространённого и метастатического рака молочной железы. СПб.: Грифон, 1997.

Семиглазов В.Ф., Попова Р. Т. Диагностика билатерального рака молочной железы. Первично-множественные злокачественные опухоли (ред. Напалков Н.П., Бохман Я.В., Семиглазов В.Ф.). Ленинград, 1987, с. 7—16.

Тихонова Л.И. Общий обзор ситуации с инфекциями, передаваемыми половым путем. Анализ заболеваемости врожденным сифилисом в Российской Федерации. Вест, дермат. венерол., 1999, № 2, с. 4—7.

Хансон К.П. Роль апоптоза в старении и возрастной патологии. Успехи геронтол., 1999, т. 3, с. 103—110.

Хансон К.П.у Имянитов Е.Н. Онкоген ERBB2/HER2: от молекулярной к клинической онкологии. Вопр. онкол, 2002, т. 48, № 2, с. 137-145.

Хансон К.П., Имянитов Е.Н. Современные представления о канцерогенезе рака шейки матки. Практич. онкол, 2002, №3, с. 145-155.

Хансон К.П., Имянитов Е.Н. Функциональная онкогеномика — новое направление в молекулярной онкологии. Молекулярная медицина, 2004, т. 1, с. 3-9.

A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project. Blood, 1997, v. 89, p. 3909-3918.

A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N. Engl. J. Med., 1993, v. 329, p. 987-994.

Abate-Shen C., Shen M.M. Molecular genetics of prostate cancer. Genes Dev., 2000, v. 14, p. 2410-2434.

Adams M., Borysiewicz L., FianderA., Man S., Jasani B., Navabi H., Lipetz C., Evans A.S., Mason M. Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer. Vaccine, 2001, v. 19, p. 2549—2556.

Adlard J. W., Richman S.D., Seymour M. T., Quirke P. Prediction of the response of colorectal cancer to systemic therapy. Lancet Oncol., 2002, v. 3, p. 75—82.

Al-Sukhun S., Hussain M. Current understanding of the biology of advanced bladder cancer. Cancer, 2003, v. 97, Suppl. 8, p. 2064—2075.

Alexander K.A., Phelps W.C. Recent advances in diagnosis and therapy of human papillomaviruses. Expert. Opin. Investig. Drugs, 2000, v. 9, p. 1753—1765.

Alexandrova Y.N., Lyshchov A.A., Safronnikova N.R., Imyanitov E.N., Hanson K.P. Features of HPV infection among the healthy attendants of gynecological practice in St. Petersburg, Russia. Cancer Lett., 1999, v. 145, p. 43—48.

Alizadeh A.A., Eisen M.B., Davis R.E., Ma C., Losses I.S., Rosenwald A., Boldrick J.C., Sabet H., Tran T., YuX., Powell J. I., YangL., Marti G.E., Moore T., Hudson J. Jr., Lu L., Lewis D.B., Tibshirani R., SherlockG., Chan W.C., Greiner T.C., Weisenburger D.D., Armitage J.O., Wamke R., Levy R., Wilson W., Grever M.R., Byrd J.C., Botstein D., Brown P.O., Staudt L.M. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature, 2000, v. 403, p. 503— 511.

An H.X., ClaasA., Savelyeva L., Seitz S., Schlag P., Scherneck S., Schwab M. Two regions of deletion in 9p23-24 in sporadic breast cancer. Cancer Res., 1999, v. 59, p. 3941-3943.

Anisimov V.N. Age as a risk factor in multistage carcinogeneis. In «Comprehensive Geriatric Oncology» (eds. Balducci L., Lyman G.H., Ershler W.B.), Harwood Academic Publishers, 1998, p. 157-178.

Anzick S.L., KononenJ., Walker R.L.,Azprsa D.O., Tanner M.M., Guan X.Y., Sauter G., Kallioniemi O.P., Trent J.M., Meltzer P.S. AIBl, a steroid receptor coactivator amplified in breast and ovarian cancer. Science, 1997, v. 277, p. 965—968.

Arun B., Goss P. The role of COX-2 inhibition in breast cancer treatment and prevention. Semin. Oncol., 2004, v. 31, Suppl. 7, p. 22—29.

Список литературы

Aschele С., Lonardi S., Monfardini S. Thymidylate Synthase expression as a predictor of clinical response to fluoropyrimidine-based chemotherapy in advanced colorectal cancer. Cancer Treat Rev., 2002, v. 28, p. 27—47.

Atkins M.B., Avigan D.E., Bukowski R.M., Childs R. W., DutcherJ.P., Eisen T.G., Figlin R.A., Finke J.H., Flanigan R.C., George D.J., Goldberg S.N., Gordon M.S., fliopoulos O., Kaelin W.G. Jr., Linehan W.M., Lipton A., Motzer R.J., Novick A.C., Stadler W.M., Teh B.T., Yang J.C., King L. Innovations and challenges in renal cancer: consensus statement from the first international conference. Clin. Cancer Res., 2004a, v. 10 (18 Pt 2), p. 6277S-6281S.

Atkins M.B., Regan M., McDermott D. Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clin. Cancer Res., 2004b, v. 10 (18 Pt 2), p. 6342S-6346S.

Baltimore D. Our genome unveiled. Nature, 2001, v. 409, p. 814—816.

Barakat M.T., Meeran K, Bloom S.R. Neuroendocrine tumours. Endocr. Relat. Cancer, 2004, v. 11, p. 1—18.

Barasso R. Colposcopic diagnosis of HPVcervical lesions. In: Munoz N., Bosch F.X., Shah K.V., Meheus A (eds) The epidemiology of cervical and human papillomavirus. Lyon, France: IARC, 1992, p. 67-74.

Borland M., Forozan F., KononenJ., BubendotfL., Chen Y., Bittner M.L., Torhorst J., HaasP., BucherC., SauterG., KallioniemiO.P., Kallioniemi A. Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. J. Natl. Cancer Inst., 2000, v. 92, p. 1252-1259.

BarlundM., MonniO., KononenJ., Comelison R., Torhorst J., SauterG., Kallioniemi O.P., Kallioniemi A. Multiple genes at 17q23 undergo amplification and overexpression in breast cancer. Cancer Res., 2000, v. 60, p. 5340-5344.

Bauer H.M., Manos m.m. PCR detection of genital human papillomavirus, in: D.H. Persing (Ed.), Diagnostic Molecular Microbiology. Washington DC, 1993, p. 407-419.

Baylin S.B., Herman J.G., Graff J.R., Vertino P.M., Issa J.P. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv. Cancer Res., 1998, v. 72, p. 141-196.

Bellacosa A. Genetic hits and mutation rate in colorectal tumorigenesis: versatility of Knudson’s theory and implications for cancer prevention. Genes Chromosomes Cancer, 2003, v. 38, 382—388.

Belogubova E.V., Togo A.V., Kondratieva T.V., Lemehov KG., Hanson K.P., Imyanitov E.N. GSTM1 genotypes in elderly tumour-free smokers and non-smokers. Lung Cancer, 2000, v. 29, p. 189-195.

Beral V., Peterman T, Berkelman R., Jaffe H. AIDS-associated non-Hodgkin lymphoma. Lancet, 1991, v. 338, p. 884-885.

Beral V., Day N. Screening for cervical cancer: is there a place for incorporating tests for the human papillomavirus? In: Munoz N., Bosch F.X., Shah K.V., Meheus A. (Eds) The epidemiology of cervical and human papillomavirus. Lyon, France: IARC, 1992, p. 263-269.

Bernard Н. U., Chan S. Y., Manos М.М., OngC.K., Villa L.L., Delius H., Peyton C.L., Bauer H.M., WheelerC.M. Identification and assessment of known and novel human papillomaviruses by polymerase chain reaction amplification, restriction fragment length polymorphisms, nucleotide sequence, and phylogenetic algorithms. J. Infect. Dis., 1994, v. 170, p. 1077-1085.

Bertram J.S. The molecular biology of cancer. Mol. Aspects. Med., 2000, v. 21, p. 167-223.

Bertucci F., Viens P., Hingamp P, Nasser V., Houlgatte R., Birnbaum D. Breast cancer revisited using DNA array-based gene expression profiling. Int. J. Cancer, 2003, v. 103, p. 565-571.

Bittner M., Meltzer P, Chen Y, Jiang Y., SeftorE., Hendrix M., Radmacher M., Simon R., Yakhini Z., Ben-Dor A., Sampas N., Dougherty E., Wang E., Marincola F., Gooden C, LuedersJ., GlatfelterA., Pollock P, CarptenJ., GiHanders E., Leja D., Dietrich K., Beaudry C, Berens M., Alberts D., Sondak V. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature, 2000, v. 406, p. 536—540.

Bodmer D., van den Hurk W., van Groningen J.J., Eleveld M.J., Martens G.J., Weterman M.A., van KesselA.G. Understanding familial and non-familial renal cell cancer. Hum. Mol. Genet., 2002, v. 11, p. 2489—2498.

Bosch F.X., Manos M.M., Munoz N., Sherman M., Jansen A.M., Peto J., Schiffman M.H., Moreno V., Kurman R., Shah K.V. Prevalence of Human papillomavirus in cervical cancer — a worldwide perspective. J. Natl. Cancer Inst., 1995, v. 87, p. 796-802.

Bosch F.X., LorinczA., Munoz N., MeijerC.J., Shah K.V. The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol., 2002, v. 55, p. 244-265.

BoursnellM.E., RutherfordE., HicklingJ.K, MeijerC.J., Shah К. V. Construction and characterisation of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer. Vaccine, 1996, v. 14, p. 1485-1494.

Boyle P., Leon M.E. Epidemiology of colorectal cancer. Br. Med. Bull., 2002, v. 64, p. 1-25.

Boyle P, Maisonneuve P., Napalkov P. Incidence of prostate cancer will double by the year 2030: the argument for. Eur. Urol., 1996, v. 29, Suppl. 2, p. 3—9.

Brauers A., Jakse G. Epidemiology and biology of human urinary bladder cancer. J. Cancer Res. Clin. Oncol., 2000, v. 126, p. 575—583.

Browne C.M., Hime G.R., Koopman P., Loveland K.L. Genetic basis of human testicular germ cell cancer: insights from the fruitfly and mouse. Cell Tissue Res., 2005, v. 322, p. 5-19.

Bubendorf L., Kolmer M., Kononen J., Koivisto P., Mousses S., Chen Y., Mahlamaki E., Schraml P., Moch H., Willi N., Elkahloun A.G., Pretlow T.G., Gasser T.C., Mihatsch M.J., SauterG., Kallioniemi О. P. Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. J. Natl. Cancer Inst., 1999, v. 91, p. 1758-1764.

Список литературы

Bubendorf L., Kononen J., Koivisto P., Schraml P., Moch H., Gasser T.C., Willi N., Mihatsch M.J., SauterG., Kallioniemi O.P. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res., 1999, v. 59, p. 803—806.

Bubendorf L., Nocito A., Moch H., Sauter G. Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies. J. Pathol., 2001, v. 195, p. 72-79.

Bufill J.A. Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann. Intern. Med., 1990, v. 113, p. 779—788

Burton A. What went wrong with Iressa? Lancet Oncol., 2002, v. 3, p. 708.

Caldas C., Ponder B.A.J. Cancer genes and molecular oncology in the clinic. Lancet, 1997, v. 349, Suppl. II, p. 16-18.

Cahill D.P., Kinzler K.W., Vogelstein B., Lengauer C. Genetic instability and darwinian selection in tumours. Trends Cell Biol., 1999, v. 9, p. M57—60.

Campos S. M. Aromatase inhibitors for breast cancer in postmenopausal women. Oncologist, 2004, v. 9, p. 126—136.

Capdeville R., Buchdunger E., Zimmermann J., Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat. Rev. Drug Discov., 2002, v. 1, p. 493-502.

Carbone P.P., Kaplan H.S., Musshoff K, Smithers D. W., Tubiana M. Report of the Committee on Hodgkin’s Disease Staging Classification. Cancer Res., 1971, v. 31, p. 1860-1861.

Casey G. The BRCA1 and BRCA2breast cancergenes. Curr. Opin. Oncol., 1997, v. 9, p. 88-93.

Caporaso N., Goldstein A. Issues involving biomarkers in the study of the genetics of human cancer. IARC Sci. Publ., 1997, v. 142, p. 237—250.

Chabner B.A. The miracle of Iressa. Oncologist, 2004, v. 9, p. 245—246.

Chabner B.A., Roberts T.G. Jr. Timeline: Chemotherapy and the war on cancer. Nat. Rev. Cancer, 2005, v. 5, p. 65-72.

Chan S.K, Gullick W.J., Hill M.E. Mutations of the epidermal growth factor receptor in non-small cell lung cancer — search and destroy. Eur. J. Cancer, 2006, v. 42, p. 17-23.

Chiusolo P., Reddiconto G., Casorelli /., Laurenti L., Sora F., Mele L., Annino L., Leone G., Sica S. Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate. Ann. Oncol., 2002. v. 13, p. 1915-1918.

Chouchane L., Ahmed S.B., Baccouche S., Remadi S. Polymorphism in the tumor necrosis factor-alpha promotor region and in the heat shock protein 70 genes associated with malignant tumors. Cancer, 1997, v. 80, p. 1489-1496.

Chandrase/charappa S.C., Guru S.C., Manickam P., Olufemi S.E., Collins P.S., Emmert-Buck M.R., Debelenko L. V., ZhuangZ., Lubensky I.A., Liotta L.A., Crabtree J.S., Wang Y., Roe B.A., Weisemann J., Boguski M.S., AgarwalS.K., Kester M.B., Kim Y.S., HeppnerC., DongQ., SpiegelA.M., BurnsA.L., MarxS.J. Positional cloning of

the gene for multiple endocrine neoplasia-type 1. Science, 1997, v. 276, p, 404— 407.

Cheng K.C., Cahill D.S., Kasai H., Nishimura S, Loeb LA. 8-Hydroxyguanine, an abundant form of oxidative DNA damage, causes G-T and A-C substitutions. J. Biol. Chem., 1992, v. 267, p. 166-172.

Chidambaram A., Dean M. Genetics of the nevoid basal cell carcinoma syndrome. Adv. Cancer Res., 1996, v. 70, p. 49—61.

Ciardiello F., De Vita F., Orditura M., Tortora G. The role of EGFR inhibitors in nonsmall cell lung cancer. Curr. Opin. Oncol., 2004, v. 16, p. 130—135.

Ciccolini J., EvrardA., Cuq P. Thymidine phosphorylase and fluoropyrimidines efficacy: a Jekyll and Hyde story. Curr. Med. Chem. Anticancer Agents, 2004, v. 4, p. 71—81.

Clark E.A., Golub T.R., Lander E.S., Hynes R.O. Genomic analysis of metastasis reveals an essential role for RhoC. Nature, 2000, v. 406, p. 532—535.

Clarke C. A., Glaser S.L. Changing incidence of non-Hodgkin lymphomas in the United States. Cancer, 2002, v. 94, p. 2015—2023.

Cleghorn F.R., Manns A., Falk R., Hartge P., Hanchard B., Jack N., Williams E., Jaffe E., White F., Bartholomew C., etal. Effect of human T-lymphotropic virus type I infection on non-Hodgkin’s lymphoma incidence. J. Natl. Cancer Inst., 1995, v. 87, p. 1009-1014.

Codori A.M. Psychological opportunities and hazards in predictive genetic testing for cancer risk. Gastroenterol. Clin. North Am., 1997, v. 26, p. 19-39.

Cole K.A., Krizman D.B., Emmert-Buck M.R. The genetics of cancer — a 3D model. Nat. Genet., 1999, v. 21, p. 38-41.

Collins F.S., Mansoura M.K. The Human Genome Project. Revealingthe shared inheritance of all humankind. Cancer, 2001, v. 91, p. 221-225.

Correa-Cerro L., Berthon P., HausslerJ., Bochum S., Drelon E., Mangin P, Fournier G., Paiss T., Cussenot 0., Vogel W. Vitamin D receptor polymorphisms as markers in prostate cancer. Hum Genet., 1999, v. 105, p. 281—287.

Cortopassi G., Liu Y. Genotypic selection of mitochondrial and oncogenic mutations in human tissue suggests mechanisms of age-related pathophysiology. Mutat. Res., 1995, v. 338, p. 151-159.

Coon J.S., Marcus E., Gupta-Burt S., Seelig S., Jacobson K., Chen S., Renta V., Fronda G., PreislerH.D. Amplification and overexpression of topoisomerase Ilalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin. Cancer. Res., 2002, v. 8, p. 1061-1067.

Courjal F., Сипу M., Simony-Lafontaine J., Louason G., SpeiserP., Zeillinger R., Rodriguez C., Theillet C. Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups. Cancer Res., 1997, v. 57, p. 4360-4367.

Cristofanilli M., Hortobagyi G.N. Molecular targets in breast cancer: current status and future directions. Endocr. Relat. Cancer., 2002, v. 9, p. 249—266.

CuligZ., HobischA., CronauerM. V, RadmayrC., TrapmanJ., HittmairA., Bartsch G., KlockerH. Androgen receptor activation in prostatic tumor cell lines by insulin-like

Список литературы

growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res., 1994, v. 54, p. 5474-5478.

Cuzin M. DNA chips: a new tool for genetic analysis and diagnostics. Transfus. Clin. Biol., 2001, v. 8, p. 291-296.

Da Silva D.M., Eiben G.L., Fausch S.C., Wakabayashi M. T., Rudolf M.P., Velders

M. P., Kast W.M. Cervical cancer vaccines: emerging concepts and developments. J. Cell. Physiol., 2001, v. 186, p. 169-182.

Davidson J.M., Gorringe K.L., Chin S.F., Orsetti B., Besret C., Courtay-Cahen C, Roberts I., Theillet C., Caldas C, Edwards P.A. Molecular cytogenetic analysis of breast cancer cell lines. Br. J. Cancer, 2000, v. 83, p. 1309-1317.

Davies M.A., Koul D., Dhesi H., Berman R., McDonnell T.J., McConkey D., Yung IV. K., Steck P.A. Regulation of Ant/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN. Cancer Res., 1999, v. 59, p. 2551-2556.

Davies R.J., Miller R., Coleman N. Colorectal cancer screening: prospects for molecular stool analysis. Nat. Rev. Cancer, 2005, v. 5, p. 199—209.

De Bono J.S., Tolcher A.W., Rowinsky E.K. Famesyltransferase inhibitors and their potential in the treatment of breast carcinoma. Semin. Oncol., 2003, v. 30, 5 Suppl. 16, p. 79-92.

De Bono J.S., Tolcher A. W., Rowinsky E.K. The future of cytotoxic therapy: selective cytotoxicity based on biology is the key. Breast Cancer Res., 2003, v. 5, p. 154-159.

De Jong M.M., Nolte I.M., te Meerman G.J., van derGraafW.T., de Vries E.G., Sijmons R.H., Hofstra R.M., Kleibeuker J.H. Low-penetrance genes and their nvolvement in colorectal cancer susceptibility. Cancer Epidemiol. Biomarkers Prev., 2002, v. 11, p. 1332-1352.

De Sanjose S., Santamaria M., Alonso de Ruiz P-, Aristizabal N., Guerrero E., Castellsague X., Bosch F.X. HPV types in women with normal cervical cytology. In: Munoz N., Bosch F.X., Shah K.V., Meheus A. (eds.) The epidemiology of cervical and human papillomavirus. Lyon, France: IARC, 1992, p. 75-84.

De Villiers E.M. Minireview: heterogeneity of the human papillomavirus group. J. Virol., 1989, v. 63, p. 4898-4903.

De Villiers E.M. Hybridization method other then PCR: an update. In: Munoz

N. , Bosch F.X., Shah K.V., Meheus A. (eds.) The epidemiology of cervical and human papillomavirus. Lyon, France: IARC, 1992, p. 111-119.

De Villiers E.M. Human pathogenic papillomavirus types: an update. Curr. Top. Microbiol. Immunol., 1994, v. 186, p. 1-12.

D’Errico A., Taioli E., Chen X., Vineis P. Genetic metabolic polymorphisms and the risk of cancer: a review of the literature. Biomarkers, 1996, v. 1, p. 149-173.

Di Pietro A., Vries E.G., Gietema J.A., Spierings D.C., de Jong S. Testicular germ cell tumours: the paradigm of chemo-sensitive solid tumours. Int. J. Biochem. Cell Biol., 2005, v. 37, p. 2437-2456.

Di Leo A., Gancberg D., Larsimont D., Tanner M„ Jarvinen T, Rouas G., Dolci S., Leroy J.Y., Paesmans M., Isola J., Piccart M.J. HER-2 amplification and

topoisomerase I (alpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin. Cancer Res., 2002, v. 8, p. 1107-1116.

Deligdisch L., Holinka C.F. Endometrial carcinoma: two diseases?. Cancer Detect. Prev., 1987, v. 10, p. 237—246.

Dervieux T., Meshkin B., Neri B. Pharmacogenetic testing: proofs of principle and pharmacoeconomic implications. Mutat. Res., 2005, v. 573, p. 180—194.

Devilee P., Schuuring E., van de VijverMJ., Cornelisse C.J. Recent developments in the molecular genetic understanding of breast cancer. Crit. Rev. Oncogenesis, 1994, v. 5, p. 247-270.

DeVita V.T., Heilman S., RosenbergS.A. (eds.). Cancer: Principles and Practice of Oncology (6th ed). Lippincott Williams and Wilkins, Philadelphia, 2001.

Dich J., Zahm S.H., HanbergA., Adami H.O. Pesticides and cancer. Cancer Causes Control, 1997, v. 8, p. 420-443.

Dieckmann K.P., Pichlmeier U. Clinical epidemiology of testicular germ cell tumors. World J. Urol., 2004, v. 22, p. 2-14.

Dillon E.K., de Boer W.B., Papadimitriou J.M., Turbett G.R. Microsatellite instability and loss of heterozygosity in mammary carcinoma and its probable precursors. Br. J. Cancer, 1997, v. 76, p. 156-162.

Doan T., Massarotti E. Rituximab. Drugs Today (Bare)., 2005, v. 41, p. 785— 797.

Driouch K., Briffod M., Bieche Champeme M.H., Lidereau R. Location of several putative genes possibly involved in human breast cancer progression. Cancer Res., 1998, v. 58, p. 2081—2086.

Druker B.J. Imatinib as a paradigm of targeted therapies. Adv. Cancer Res., 2004, v. 91, p. 1-30.

DunningA.M., Chiano M., Smith N.R., Dearden J., Gore M., Oakes S., Wilson C., Stratton M., Peto J., Easton D., Clayton D., Ponder 7Ы.Common BRCA1 variants and susceptibility to breast and ovarian cancer in the general population. Hum. Mol. Genet., 1997, v. 6, p. 285-289.

DunningA.M., Healey C.S., Pharoah P.D., Teare M.D., Ponder B.A., Easton D.F. A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol. Biomarkers Prev., 1999, v. 8, p. 843—854.

Emmert-BuckM.R., BonnerR.F., Smith P.D., ChuaquiR.F., ZhuangZ., Goldstein S.R., Weiss R.A., Liotta L.A. Laser capture microdissection. Science, 1996, v. 274, p. 998—1001.

Eng C., Mulligan L.M. Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and hirschsprung disease. Hum. Mutat., 1997, v. 9, p. 97-109.

EngC., VijgJ. Genetic testing: the problems and the promise. Nat. Biotechnol., 1997, v. 15, p. 422-426.

EngelL.S., Taioli E., Pfeiffer R., Garcia-Closas M., Marcus P.M., Lan Q., Boffetta P, Vineis P., Autrup H., BellD.A., Branch R.A., BrockmollerJ., DalyA.K., HeckbertS.R.,

Список литературы

Kalina /., Kang D., Katoh T, LafuenteA., Lin H.J., Romkes M., Taylor J.A., Rothman N. Pooled analysis and meta-analysis of glutathione S-transferase Ml and bladder cancer: a HuGE review. Am. J. Epidemiol., 2002, v. 156, p. 95-109.

Engelhardt M., Martens U.M. The implication of telomerase activity and telomere stability for replicative aging and cellular immortality (Review). Oncol. Rep., 1998, v. 5, p. 1043-1052.

Eshleman J.R., Markowitz S. D. Microsatellite instability in inherited and sporadic neoplasms. Curr. Opin. Oncol., 1995, v. 7, p. 83—89.

Esteva F.J., Valero V, PusztaiL., Boehnke-MichaudL., BuzdarAM., HortobagyiG.N. Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist, 2001, v. 6, p. 133-146.

Evans L.S., Hancock B.W. Non-Hodgkin lymphoma. Lancet, 2003, v. 362, p. 139-146.

Faivre J., Bouvier A.M., Bonithon-Kopp C. Epidemiology and screening of colorectal cancer. Best Pract. Res. Clin. Gastroenterol., 2002, v. 16, p. 187—199.

Fearnhead N.S., Wilding J.L., Bodmer W.F. Genetics of colorectal cancer: hereditary aspects and overview of colorectal tumorigenesis. Br. Med. Bull., 2002, v. 64, p. 27—43.

Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell, 1990, v. 61, p. 759-767.

Febbo P.G., Kantoff P. W., Platz E.A., Casey D., Batter S., Giovannucci E., Hennekens C.H., Stampfer M.J. The V89L polymorphism in the 5alpha-reductase type 2 gene and risk of prostate cancer. Cancer Res., 1999, v. 59, p. 5878—5881.

Febbo P.G. Functional significance of the androgen receptor CAG repeat polymorphism. Prostate J., 2000, v. 2, p. 14-21.

Feigal E.G. AIDS-associated malignancies: research perspectives. Biochim. Biophys. Acta, 1999, v. 1423, p. Cl—C9.

Feigelson H.S., Coetzee G.A., Kolonel L.N., Ross R.K., Henderson B.E. A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res., 1997, v. 57, p. 1063-1065.

Fernandez P, Carretero JMedina P.P., JimenezA./., Rodriguez-Perales S., Paz M.F, Cigudosa J.C., Esteller M., Lombardia L., Morente M., Sanchez-Verde L., Sotelo T., Sanchez-Cespedes M. Distinctive gene expression of human lung adenocarcinomas carrying LKB1 mutations. Oncogene, 2004, v. 23, p. 5084—5091.

FerrandinaG., ZannoniG.F., MartinelliE., PagliaA., Gallotta V, MozzettiS., Scambia G., Ferlini C. Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin. Cancer Res., 2006, v. 12, p. 2774—2779.

Ferrera A., Velema J.P., Figueroa M., Bulnes R., Toro L.A., Claros J.M., De Barahona O., Melchers W.J. Human papillomavirus infection, cervical dysplasia and invasive cervical cancer in Honduras: a case-control study. Int. J. Cancer, 1999, v. 82, p. 799-803.

Ferry J. «Working draft» of human genome available by June. Lancet, 2000, v. 355, p. 1337.

Fischer J.R., Lahm Н. Validation of molecular and immunological factors with predictive importance in lung cancer. Lung Cancer, 2004, v. 45, Suppl. 2, p. S15l-S161.

Fischer O.M., StreitS., Hart S., Ullrich A. Beyond Herceptin and Gleevec. Curr. Opin. Chem. Biol., 2003, v. 7, p. 490-495.

Folprecht G., Kohne C.H. The role of new agents in the treatment of colorectal cancer. Oncology, 2004, v. 66, p. 1-17.

Forgoes E., Zochbauer-Muller S., Olah E., Minna J.D. Molecular genetic abnormalities in the pathogenesis of human lung cancer. Pathol. Oncol. Res., 2001, v. 7, p. 6-13.

Formentini A., Henne-Bruns D., Kornmann M. Thymidylate synthase expression and prognosis of patients with gastrointestinal cancers receiving adjuvant chemotherapy: a review Langenbecks Arch. Surg., 2004, v. 389, p. 405-413.

Foster C.S., Cornford P., Forsyth L., Djamgoz M.B., Ke Y. The cellular and molecular basis of prostate cancer. BJU Int., 1999, v. 83, p. 171-194.

Franco E.L., Rohan T.E., Villa L.L. Epidemiologic evidence and human papillomavirus infection as a necessary cause of cervical cancer. J. Natl. Cancer Inst., 1999, v. 91, p. 506—511.

Frank T.S. Laboratory determination of hereditary susceptibility to breast and ovarian cancer. Arch. Pathol. Lab. Med., 1999, v. 123, p. 1023—1026.

FullerG.N., RheeC.H., Hess K.R., Caskey L.S., WangR., Bruner J.M., YungW.K., Zhang W. Reactivation of insulin-like growth factor binding protein 2 expression in glioblastoma multiforme: a revelation by parallel gene expression profiling. Cancer Res., 1999, v. 59, p. 4228-4232.

Gabrielson E., Berg K., Anbazhagan R. Functional genomics, gene arrays, and the future of pathology. Mod. Pathol., 2001, v. 14, p. 1294-1299.

Garner M.J., Turner M.C., Ghadirian P., Krewski D. Epidemiology of testicular cancer: an overview. Int. J. Cancer, 2005, v. 116, p. 331-339.

Gasco M., Shami S., Crook T. The p53 pathway in breast cancer. Breast Cancer Res., 2002, v. 4, p. 70-76.

GaytherS.A., de Foy K.A., Harrington P, Pharoah P, DunsmuirW.D., EdwardsS.M., Gillette., Ardem-JonesA., Deamaley D.P., EastonD.F, FordD., ShearerR.J., Kirby R.S., DoweA.L., Kelly J., Stratton M.R., Ponder B.A., Barnes D., EelesR.A. The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators. Cancer Res., 2000, v. 60, p. 4513-4518.

Gerrero M. R., Weber B.L. Recent advances in breast cancer biology. Curr. Opin. Oncol., 2001, v. 13, p. 415—419.

Giaccone G., Rodriguez J.A. EGFR inhibitors: what have we learned from the treatment of lung cancer? Nat. Clin. Pract. Oncol., 2005, v. 2, p. 554—561.

GibbsM., Stanford J.L., JarvikG.P., JanerM., Badzioch M., Peters M.A., Goode E.L., Kolb S., Chakrabarti L., Shook M., Bosom R., Ostrander E.A., Hood L. A genomic

Молекулярная онкология, клинические аспекты, Е.Н. Имянитов, К.П. Хансон